Orthofix International N.V. has launched its TL-HEX, or TrueLok Hexapod System, to international markets. The company displayed the system at the annual meetings of the Italian Society of Orthopaedics and Traumatology (SIOT) in Rome, Italy and the French Society of Orthopedic Surgery and Traumatology (SOFCOT) in Paris, France.
Orthofix Challenges Fixation Market
1 min read Premium comments
Secondary
The company believes this multi-planar system together with the associated software will provide access to the largest segment of the circular and hybrid fixation markets long dominated by one product.
The system, an external hexapod ring-type fixator for deformity correction and complex trauma treatment, was co-developed with the company’s partner, the Texas Scottish Rite Hospital for Children. That partnership was recently extended through 2018.
Bob Vaters, Orthofix’s president and CEO, said the company is a global leader of external fixation and the TRU-HEX “truly improves the lives of patients who are suffering from orthopedic deformities or from trauma.”
The first surgery using the system was performed by Dr. Franz Birkholtz in South Africa in November.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.